$CLYM

Raymond James maintained a Strong Buy rating and $34.00 price target for Climb Bio (NASDAQ:CLYM) after Phase 2 budoprutug data abstract release. The stock is up 453% over a year, trading at $10.94. Analysts' targets range from $18 to $40, with a consensus Strong Buy. Initial data shows safety and B cell depletion, with a full presentation expected on October 24. Recent Phase 1 trial results for CLYM116 also led to multiple analyst upgrades and higher price targets.

Climb Bio (NASDAQ:CLYM) will present Phase 2 data for its kidney disease therapies, CLYM116 and budoprutug, at the American Society of Nephrology Kidney Week 2026. Budoprutug, with FDA designations, is in trials for multiple conditions, while CLYM116 targets IgA nephropathy.

Raymond James updated its Healthcare Top Picks for October, adding Xencor (XNCR), Calyxt (CLYM), and UnitedHealth Group (UNH), while removing Relay Therapeutics, Tyra Biosciences, and Oscar Health. The firm cited near-term catalysts for Xencor and Calyxt, and expects strong earnings from UnitedHealth.

Thomas Stephen Basil sold 100,000 shares of Climb Bio, Inc. (CLYM) at $13.67 ($1.37M total) on 2026-09-15 under a Rule 10b5-1 trading plan.

Climb Bio (CLYM) stock fell 7% to $14.00 in pre-market trading after releasing Phase 1 clinical data for CLYM116, showing near-complete APRIL protein suppression and sustained IgA reductions. The decline follows a 'buy the rumor, sell the news' pattern, with investors taking profits after the data release. The company's Phase 2 trial data is not expected until 2027, contributing to the pullback. The broader market showed modest gains, with the S&P 500, Dow Jones, and Nasdaq up 0.3%, 0.6%, and 0.

Climb Bio (CLYM) reported positive Phase 1 data for CLYM116, showing a 29-day half-life, 90% APRIL suppression, and 60-75% IgA suppression. The drug was well-tolerated. Phase 2 trial data is expected in H1 2027, with Phase 3 initiation planned for 2027. The company will host a webcast on September 3.

Climb Bio, Inc. (CLYM) shares rose 17% after reporting positive Phase 1 trial results for CLYM116, its anti-APRIL monoclonal antibody. The drug showed near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression, with a half-life of 29 days. The trial enrolled 46 subjects and reported no serious adverse events. The company plans to present additional data in Q4 2026 and anticipates Phase 2 trial results in H1 2027.

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates CLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026 Anticipate CLYM116 Phase 2 trial in IgA nephropathy to initiate dosing in Q3 2

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001768446 0001768446 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29,

Climb Bio, Inc. (CLYM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d92589dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 OPEN MARKET SALE AGREEMENT SM June 12, 2026 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Climb Bio, Inc., a Delaware corporation (the “ Company ”), proposes, subject to the terms and conditions